Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients with COPD


First-in-world approval of Dupixent for adults with uncontrolled COPD with raised blood eosinophils based on two landmark Phase 3 trials showing Dupixent significantly reduced exacerbations, improved lung function and also improved health-related quality of life

See the original post:
Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients with COPD

Related Posts